NewsRx

Search our medical news database

Type 2 Diabetes

Data shows potential of arimoclomol as a therapeutic for type 2 diabetes

Published in Drug Week, February 11th, 2005

CytRx Corp. (CYTR) announced previously unreleased scientific data showing the potential of its oral drug candidate arimoclomol as a therapeutic for type 2 diabetes.

The data was included in a poster entitled "The Broad Therapeutic Potential of Pharmaceuticals that Activate Molecular Chaperone Proteins," presented at the Protein Folding Disorders Conference in San Diego, California.

"We previously announced data showing that arimoclomol restored normal serum glucose levels in an animal model when co-administered with a commonly prescribed drug, metformin," said Steven A. Kriegsman, president and CEO of CytRx.

"The data that we are...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook